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Copyright © 2008 JCBN Summary Linoleic acid (LA) preincubated with cyclooxygenase (COX)-1 or -2 inhibited
prostaglandin (PG) formation from arachidonic acid (AA) catalyzed by the respective enzyme,
but LA without the preincubation did not. 13S-Hydroperoxy-9Z,11E-octadecadienoic acid (13-
HPODE) a hydroperoxy adduct of LA inhibited PG formation catalyzed by COX-1 or -2. 13S-
Hydroxy-9Z,11E-octadecadienoic acid had no effect on both COX-1 and -2 activities. These
results suggest that 13-HPODE which is preformed from LA by COX reaction under normal
physiological conditions can be a basal suppressor of PG formation from AA.
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Introduction
Prostaglandins (PGs) are critical mediators of a variety of
physiological and pathophysiological processes. The initial
step in the biosynthesis of these bioactive lipids is accom-
plished by cyclooxygenase (COX), which catalyzes the
conversion of arachidonic acid (AA) to PGG2 and H2. Two
COX isoforms have been identified and are referred to as
COX-1 and COX-2 [1]. COX-1 is ubiquitous enzyme and it
appears to perform many homeostatic functions [2–4].
COX-2 is generally thought to be an enzyme synthesized in
response to inflammatory stimuli [2–4]. There are lots of
published data concerning the differential roles of COX-1
and -2 on the physiological and pathophysiological func-
tions, but it is unclear about differences in the endogenous
regulation of these two isoforms in the body.
Up to date, it has been widely accepted that linoleic acid
(LA) is a competitive inhibitor of COX-1 activity [5–7].
Ringbom et al. [8] have found that LA is also an inhibitor of
COX-2, and the inhibitory potency on the COX-2 is more
than that on the COX-1. On the other hand, many investiga-
tors [9, 10] including us [11] have shown that LA is trans-
formed into hydroperoxides by COX reactions. Laneuville
et al. [12] have shown that both COX-1 and -2 prepared
from COS-1 cells metabolized LA, and that 13S-
hydroperoxy-9Z,11E-octadecadienoic acid (13-HPODE)
was the main product of both reactions. There is little
information concerning a difference of potency of 13-
HPODE on the COX-1 and -2 activities. Therefore, we
investigated the effects of LA without or with preincubation
using COX-1 or -2 on the PG formation from AA by the
respective enzyme.
Materials and Methods
Materials
COX-1 (isolated from ram seminal vesicles) and COX-2
(isolated from sheep placenta) were purchased from Cayman
(Ann Arbor, MI). Sodium salt of LA was purchased
from Sigma (St Louis, MO). 13-HPODE and 13S-hydroxy-
9Z,11E-octadecadienoic acid (13-HODE) were purchasedY. Fujimoto et al.
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from Cascade Biochem. Limited (Berkshire, England). 9-
Anthryldiazomethane (ADAM) was obtained from Funa-
koshi Pharmaceutical (Tokyo, Japan). All other reagents
were of analytical grade.
Assay of PG formation from AA by COX-1 and -2
Ten units of COX-1 or -2 were incubated with 100 μM
AA in 0.5 ml of 0.1 M Tris/HCl buffer (pH 8.0) containing
hematin (0.1 μM) and phenol (2 mM) as cofactors for 2 min
at 37°C. 13-HPODE, 13-HODE or LA was added in the
incubation mixture at t = 0. In Table 1, LA was also preincu-
bated with COX-1 or -2 for 10 min prior to the incubation
with AA. After incubation, the reaction mixture was ex-
tracted with 6 vol. of n-hexane:ethyl acetate (2:1, v/v). The
aqueous phase was then acidified (approximately pH 3) with
2 N HCl and extracted with 6 vol. of ethyl acetate. PGE2, D2
and F2α in the extracted lipid were simultaneously deter-
mined by an HPLC using ADAM for derivatization, as de-
scribed in our previous studies [13, 14]. Peak heights were
measured for the quantification of ADAM derivatives of
PGs relative to the standard derivatives prepared from
authentic PGs. The recoveries of PGs during extraction were
between 90% and 99%.
Statistical analysis
Results are presented as mean ± SE. Statistical signifi-
cance was calculated by Student’s paired t-test.
Results and Discussion
In the present study, when either COX-1 or -2 was incu-
bated with AA, PGE2 was mainly formed in both reaction
mixtures (77–79%). Lesser amounts of PGD2 and F2α were
also made by these two enzymes (PGD2, 18–20%; PGF2α,
3%). It has been reported that indomethacin inhibits both
COX-1 and -2 activities, but NS-398 selectively inhibits
COX-2 activity [15]. Our previous study [16] utilizing
indomethacin and NS-398 has demonstrated that PGE2
formations by the present assay conditions exactly reflect
the activities of COX-1 and -2. Therefore, we evaluated the
COX-1 and -2 activities by measuring the amounts of PGE2
formed from AA.
Table 1 illustrated the effects of LA without or with
preincubation using COX-1 or -2 on PG formation from AA
catalyzed by the respective enzyme. Co-addition of 5 μM
LA in the reaction mixture did not show any significant
change in PG formation catalyzed by both enzymes. This
inability of 5 μM LA is explained by the previous finding by
Ringbom et al. [8], which showed that a competitive inhibi-
tion by LA on the COX-1 and -2 activities became clear at
much higher concentrations (IC50: 170 μM for COX-1;
94 μM for COX-2). In contrast, 5 μM LA preincubated for
10 min with COX-1 or -2 strongly inhibited the PG forma-
tion catalyzed by the respective enzyme, and the inhibition
on the COX-2 (95% inhibition) was somewhat stronger than
that on the COX-1 (74% inhibition).
It has been shown that LA is transformed into 13-HPODE
by COX-1 and -2, and that 13-HPODE is further decom-
posed to form 13-HODE by enzymatic and non-enzymatic
pathways [9–12]. To investigate the inhibitory effect of
preincubated LA on COX-1 or -2 activity, the effects of
13-HPODE and 13-HODE on the enzyme activities were
examined (Table 2). 13-HPODE inhibited PG formation
catalyzed by both COX-1 and -2, and the concentrations
required to inhibit the enzyme activities by 50% (IC50) were
3.1 μM for COX-1 and 1.5 μM for COX-2. So, the inhibi-
tory effect of 13-HPODE on the PG formation catalyzed by
COX-2 was about two times stronger than that by COX-1.
On the other hand, 13-HODE did not affect PG formation
catalyzed by both COX-1 and -2 (IC50, over 10 μM). We also
confirmed that LA was rapidly converted into 13-HODE by
COX-2; 13-HODE (1.2 nmol) was detected by HPLC-UV
apparatus, when 100 μM LA was incubated with COX-2 (10
units) for 1 min (n = 2). Therefore, these findings indicate
that 13-HPODE formed from LA during preincubation with
COX-1 or -2 can be a potent inhibitor of PG formation from
AA by the respective enzyme.
Table 1. Effects of LA without or with preincubation using
COX-1 or -2 on prostaglandin formation from AA
catalyzed by the respective enzyme.
10 units of COX-1 or -2 were incubated with 100 μM arachidonic
acid (AA) for 2 min at 37°C. (a); Linoleic acid (LA) was added to
the incubation mixture at t = 0. (b); LA was preincubated with
COX-1 or -2 for 10 min prior to the incubation with AA: Values
are means ± SE (n = 5). * p<0.01, compared with control
Drugs
COX-1 activity COX-2 activity
% of control
Control 100.0 ± 9.8 100 ± 7.1
5 μM LAa 88.3 ± 7.6 85.0 ± 6.1
5 μM LAb 25.5 ± 4.9* 4.8 ± 4.9*
Table 2. Inhibition of COX-1 or -2-catalyzed prostaglandin
formation from AA by 13-HPODE.
10 units of COX-1 or -2 were incubated with 13S-hydroperoxy-
9Z,11E-octadecadienoic acid (13-HPODE) or 13S-hydroxy-9Z,11E-
octadecadienoic acid (13-HODE) at concentrations of 0.5–10 μM
in the presence of 100 μM arachidonic acid (AA) for 2 min. Values
are obtained from four dose-dependent curves on the COX-1 and
-2 activities.
COX-1 COX-2
(IC50 values, μM)
13-HPODE 3.1 ± 0.3 1.5 ± 0.2
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It is unclear about the mechanism by which 13-HPODE
has an inhibitory effect on the COX-1 and -2 activities, and
the effect on COX-2 activity is stronger than that on COX-1
activity. But, very low concentrations of hydroperoxides are
required to activate COX, and in the absence, there is very
little enzyme activity [17]. On the other hand, higher
concentrations of these substances can inhibit COX [18, 19].
Since a discovery of COX-1 and -2 isoforms in living cells,
Chen  et al. [ 20] and Liu et al. [ 21] have reported that
exogenously added peroxides decrease or abolish PGG2-
derived self-activation of COX-1 and -2, with a higher
efficacy on the COX-2. Therefore, it seems likely that the
inhibitory effect on COX-1 and -2 activities is ascribed to
lipid hydroperoxide-derived inactivation mechanism, and
COX-2 is more sensitive to lipid hydroperoxides than
COX-1.
Excess amounts of PGs have various toxic effects in the
body. Thus, it is thought that PGs produced by COX-1 being
constitutively expressed and acting for homeostatic control
are maintained at extremely low levels. Ringbom et al. [8]
have shown that a competitive inhibition by LA on the
COX-1 and -2 activities become clear at much higher
concentrations (IC50: 170 μM for COX-1; 94 μM for COX-
2) in-vitro. However, we can consider that basal appearance
of free LA in vivo is continuous upon physiological stimuli;
namely free LA in physiological conditions is rather high
compared to free AA because of a difference of total
amounts of LA and AA in vivo [ 22,  23]. Therefore, it
appears that 13-HPODE preformed by constitutively
expressed COX-1 might be an important homeostatic sup-
pressor of PG formation by this enzyme. Further, its stronger
inhibition on the activity of COX-2 by 13-HPODE observed
in the present study led us to speculate its protective role on
excess production of PGs by COX-2 in early pathophysio-
logical states.
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